natgillin/translations-raw huggingface dataset:
Senshio has been compared with placebo (a dummy treatment) in two main studies involving over 1,700 postmenopausal women with vulvovaginal atrophy.
Zdravilo Senshio so primerjali s placebom (zdravilom brez učinkovine) v dveh glavnih študijah, ki sta vključevali več kot 1 700 žensk po menopavzi z atrofijo vulve in vagine.
Some women must not use Senshio, including those who have or have had problems with blood clots in veins such as deep-vein thrombosis (DVT), pulmonary embolism (a blood clot in the lungs) and retinal-vein thrombosis (a blood clot at the back of the eye).
Nekatere ženske ne smejo uporabljati zdravila Senshio, med drugim tiste, ki imajo ali so imele težave s krvnimi strdki v venah, kot so globoka venska tromboza, pljučna embolija (krvni strdek v pljučih) in tromboza mrežnične vene (krvni strdek v zadnjem delu očesa).
Why is Senshio approved?
Zakaj je bilo zdravilo Senshio odobreno?
For the full list of side effects and restrictionsof Senshio, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri zdravilu Senshio glejte navodilo za uporabo.
The most commonly reported side effects with Senshio (affecting up to 1 in 10 people) are vulvovaginal candidiasis and other mycotic (fungal) infections, hot flushes, headache, muscle spasms, vaginal bleeding, vaginal and genital discharge, and rash.
Neželeni učinki, o katerih so najpogosteje poročali pri uporabi zdravila Senshio (ki se lahko pojavijo pri največ 1 od 10 bolnic), so vulvovaginalna kandidiaza in druge mikotične (glivične) okužbe, vročinski oblivi, glavobol, mišični krči, krvavitev iz vagine, izcedek iz vagine in spolovil ter izpuščaj.
Regarding pain during sexual activity, 58% of women using Senshio reported relief in the first study (compared with 42% receiving placebo) and 63% reported relief during the second study (compared with 48% receiving placebo).
Kar zadeva bolečine med spolno aktivnostjo, je v prvi študiji o njihovem zmanjšanju poročalo 58 % žensk, ki so uporabljale zdravilo Senshio (v primerjavi z 42 % tistih, ki so uporabljale placebo), v drugi študiji pa so se bolečine zmanjšale pri 63 % žensk, ki so uporabljale zdravilo Senshio (v primerjavi z 48 % tistih, ki so uporabljale placebo).
In the second study, 62% of women using Senshio reported relief from vaginal dryness after 12 weeks (compared with 53% in the placebo group).
V drugi študiji je o zmanjšanju suhosti vagine po 12 tednih poročalo 62 % žensk, ki so uporabljale zdravilo Senshio (v primerjavi s 53 % v skupini, ki je prejemala placebo).
In the first study, 66% of women using Senshio reported relief from vaginal dryness (mild or no symptoms) after 12 weeks' treatment compared with 49% in the placebo group.
V prvi študiji je 66 % žensk, ki so uporabljale zdravilo Senshio, po 12 tednih zdravljenja poročalo o zmanjšanju suhosti vagine (blagi simptomi ali odsotnost simptomov) v primerjavi z 49 % v skupini, ki je prejemala placebo.
Senshio improved symptoms of vulvovaginal atrophy in postmenopausal women.
Zdravilo Senshio je izboljšalo simptome atrofije vulve in vagine pri ženskah po menopavzi.
Senshio is a medicine used to treat moderate to severe symptoms of vulvovaginal atrophy (dryness, irritation and soreness around the genital area, and painful sexual intercourse) in women who have been through the menopause.
Zdravilo Senshio se uporablja za zdravljenje zmernih do hudih simptomov atrofije vulve in vagine (suhosti, draženja in bolečin v predelu genitalij ter bolečega spolnega odnosa) pri ženskah po menopavzi.
How does Senshio work?
Kako zdravilo Senshio deluje?
How is Senshio used?
Kako se zdravilo Senshio uporablja?
This can cause irritation and soreness and make sexual intercourse painful.The active substance in Senshio, ospemifene, is a selective oestrogen receptor modulator (SERM).
Učinkovina v zdravilu Senshio (ospemifen) je selektivni modulator estrogenskih receptorjev (SERM).
This summary was last updated in December 2017.
Povzetek je bil nazadnje posodobljen decembra 2017.
The full EPAR for Suvaxyn Circo can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila Suvaxyn Circo je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
This will help protect the pigs against porcine circovirus infections.
To bo prašičem pomagalo pri zaščiti pred okužbami s prašičjim cirkovirusom.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Suvaxyn Circo's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila Suvaxyn Circo večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
This is a summary of the European public assessment report (EPAR) for Suvaxyn Circo.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Suvaxyn Circo.
The vaccine contains small amounts of a protein from PCV2 that have been killed (inactivated) so that they do not cause disease.
Cepivo vsebuje majhne količine beljakovine iz virusa PCV2, ki so bile uničene (inaktivirane), tako da ne povzročajo bolezni.
In the future, if the animals come into contact with the virus the immune system will be able to respond quickly to destroy the virus.
Ob ponovni izpostavitvi živali virusu v prihodnosti se bo imunski sistem tako hitro odzval in uničil virus.
The purpose of these studies was to establish how long it took pigs to be fully protected and how long the protection against PCV2 lasted.
Namen teh študij je bil ugotoviti, po kolikem času je nastopila popolna zaščita prašičev pred virusom PCV2 in kako dolgo je ta zaščita trajala.
The most common side effects with Suvaxyn Circo (which may affect more than 1 in 10 animals) are a short-lived increase in body temperature during the first 24 hours after vaccination and swelling (generally no wider than 2 cm) at the injection site which may last for up to 2 days.
Najpogostejša neželena učinka zdravila Suvaxyn Circo (ki lahko prizadeneta več kot 1 žival od 10) sta kratkotrajno povečanje telesne temperature v prvih 24 urah po cepljenju in oteklina (običajno ne večjega premera od 2 cm) na mestu cepljenja, ki lahko traja do dva dni.
Infections can produce clinical signs such as weight loss or failure to grow, enlarged lymph nodes, difficulty breathing, pale skin and jaundice (yellowing of the skin).
Okužbe se kažejo s kliničnimi znaki, kot so zmanjšanje telesne mase ali zastoj rasti, povečane bezgavke, oteženo dihanje, bleda koža in zlatenica (rumeno obarvanje kože).
The studies showed that the vaccine had its full effect against PCV2 by three weeks after vaccination.
Študije so pokazale, da je cepivo svoj polni učinek proti virusu PCV2 doseglo v treh tednih po cepljenju.
Suvaxyn Circo also contains adjuvants (ingredients that strengthen the immune response) called squalane, poloxamer 401 and polysorbate 80.
Zdravilo Suvaxyn Circo vsebuje tudi adjuvanse (sestavine, ki pomagajo okrepiti imunski odziv), in sicer skvalan, poloksamer 401 in polisorbat 80.
The European Commission granted a marketing authorisation valid throughout the EU for Suvaxyn Circo on 7 February 2018.
Evropska komisija je dovoljenje za promet z zdravilom Suvaxyn Circo, veljavno po vsej Evropski uniji, izdala 07/02/2018.
The studies on the effectiveness of Suvaxyn Circo were carried out with a similar vaccine, Suvaxyn Circo+MH RTU, which contains PCV2 and the bacteria Mycoplasma hyopneumoniae.
Študije o učinkovitosti zdravila Suvaxyn Circo so izvedli s podobnim cepivom, Suvaxyn Circo+MH RTU, ki vsebuje virus PCV2 in bakterijo Mycoplasma hyopneumoniae.
Other information about Suvaxyn Circo
Druge informacije o zdravilu Suvaxyn Circo
Suvaxyn Circo+MH RTU is already approved in the EU.
Zdravilo Suvaxyn Circo+MH RTU je že odobreno v EU.
Suvaxyn Circo, which is available as a liquid for injection, is given to pigs from three weeks of age as a single injection into the muscle in the neck behind the ear.
Zdravilo Suvaxyn Circo, ki je na voljo kot tekočina za injiciranje, se daje prašičem, starejšim od treh tednov, kot enkratna injekcija v mišico v vrat za uho.
The withdrawal period for meat from pigs treated with Suvaxyn Circo is ‘zero' days, which means there is no mandatory waiting time.
Karenca za meso prašičev, zdravljenih z zdravilom Suvaxyn Circo, je nič dni, kar pomeni, da ni obvezne čakalne dobe.
When Suvaxyn Circo is given to pigs the animals' immune system recognises the viral protein as ‘foreign' and makes antibodies against it.
Ko prašiči prejmejo zdravilo Suvaxyn Circo, imunski sistem živali prepozna virusne beljakovine kot „tujke“ in začne proti njim tvoriti protitelesa.
Suvaxyn Circo porcine circovirus vaccine (inactivated)
Suvaxyn Circo cepivo proti prašičjemu cirkovirusu (inaktivirano)
The effectiveness of Suvaxyn Circo+MH RTU was first studied in several laboratory studies in pigs.
Učinkovitost zdravila Suvaxyn Circo+MH RTU so najprej proučevali v več laboratorijskih študijah pri prašičih.
Suvaxyn Circo is a vaccine.
Zdravilo Suvaxyn Circo je cepivo.
The effectiveness of Suvaxyn Circo+MH RTU against PCV2 infection was also studied in three field studies.
Učinkovitost zdravila Suvaxyn Circo+MH RTU proti okužbi z virusom PCV2 so proučevali tudi v treh terenskih študijah.
Suvaxyn Circo is a veterinary vaccine used to protect pigs over the age of 3 weeks against porcine circovirus type 2 (PCV2).
Zdravilo Suvaxyn Circo je cepivo za uporabo v veterinarski medicini za zaščito prašičev od starosti treh tednov dalje pred prašičjim cirkovirusom tipa 2 (PCV2).
What is Suvaxyn Circo and what is it used for?
Kaj je zdravilo Suvaxyn Circo in za kaj se uporablja?
The field studies showed that Suvaxyn Circo reduced the PCV2 viraemia (presence of virus in the blood) compared to pigs given dummy vaccination.
Terenske študije so dokazale, da je zdravilo Suvaxyn Circo zmanjšalo viremijo z virusom PCV2 (prisotnost virusa v krvi) v primerjavi s prašiči, ki so bili cepljeni s cepivom brez zdravilne učinkovine.
For practical information about using Suvaxyn Circo, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Za praktične informacije o uporabi zdravila Suvaxyn Circo naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
For more information about treatment with Suvaxyn Circo, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Za več informacij o zdravljenju z zdravilom Suvaxyn Circo naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
For the full list of restrictions and side effects with Suvaxyn Circo, see the package leaflet.
Za celoten seznam omejitev in neželenih učinkov, o katerih so poročali pri uporabi zdravila Suvaxyn Circo, glejte navodilo za uporabo.
What are the risks associated with Suvaxyn Circo?
Kakšna tveganja so povezana z zdravilom Suvaxyn Circo?
What benefits of Suvaxyn Circo have been shown in studies?
Kakšne koristi je zdravilo Suvaxyn Circo izkazalo v študijah?
Suvaxyn Circo contains an inactivated (killed) active substance derived from porcine circovirus type 2.
Zdravilo Suvaxyn Circo vsebuje inaktivirano (uničeno) zdravilno učinkovino, pridobljeno iz prašičjega cirkovirusa tipa 2.
Why is Suvaxyn Circo approved?
Zakaj je bilo zdravilo Suvaxyn Circo odobreno?
Suvaxyn Circo is only available on prescription.
Predpisovanje in izdaja zdravila Suvaxyn Circo je le na recept.
Protection lasted 23 weeks after vaccination for PCV2.
Zaščita pred virusom PCV2 je trajala 23 tednov po cepljenju.
It is not intended to provide practical advice on how to use Suvaxyn Circo.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
How is Suvaxyn Circo used?
Kako se zdravilo Suvaxyn Circo uporablja?
How does Suvaxyn Circo work?
Kako zdravilo Suvaxyn Circo deluje?
100 mg/ml
velikost pakiranja mg/ml
Intravenous use vial (glass)
Viala (steklenih)
Name Strength Pharmaceutical Form
ime jakost farmacevtska oblika pot uporabe ovojnina vsebina (koncentracija)
Packaging
Intravenska uporaba
Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, UK
Avstrija, Belgija, Bolgarija, Ciper, Češka, Danska, Estonija,, Finska, Francija, Nemčija, Grčija, Madžarska, Islandija, Irska, Latvija, Litva, Luksemburg, Malta, Nizozemska, Norveška, Poljska, Portugalska, Romunija, Slovaška, Slovenija, Španija, Švedska, Velika Britanija
Try to take the tablet at the same time each day.
Tableto poskusite vzeti vsak dan ob istem času.
Just take the next dose as normal.
Vzemite le naslednji odmerek kot po navadi.
If this happens to you, do not drive or use any tools or machines.
Če se vam to zgodi, ne vozite in ne uporabljajte orodij oziroma strojev.
Other sections were also harmonised.
Usklajena so bila tudi druga poglavja.
• Changes in blood test results:
• Spremembe izvidov preiskav krvi:
This conclusion was confirmed also in another study which looked at an even higher starting dose.
Ta zaključek potrjuje tudi druga študija, v kateri so proučevali še višji začetni odmerek.
Taking Atacand with food and drink (in particular alcohol)
Jemanje zdravila Atacand skupaj s hrano in pijačo (zlasti z alkoholom)
Atacand is indicated for the:
Atacand je indiciran za:
This is medicine is used for:
To zdravilo se uporablja za:
It also makes it easier for your heart to pump blood to all parts of your body.
Srcu tudi olajša črpanje krvi v vse dele telesa.
{Name and address of the manufacturer} <{tel}> <{fax}> <{e-mail}>
{Ime in naslov izdelovalca} <{tel.}> <{faks}> <{e-pošta}>
• A reduction in your red or white blood cells.
• Zmanjšanje števila rdečih ali belih krvnih celic.
Therefore, the use of Atacand is not recommended in this population.
Zato uporaba Atacanda v tej populaciji ni priporočljiva.
Swallow the tablet with a drink of water.
Tableto zaužijte s kozarcem vode.
The agreed indications were:
Dogovorjene indikacije so bile:
The combination should be administered with caution, especially in the elderly.
To kombinacijo je treba uporabljati previdno, še posebno pri starejših.
Most of the antihypertensive effect is attained within 4 weeks.
Večina antihipertenzivnega učinka je doseženega v 4 tednih.
Non-Perforated calendar foil (7, 14, 28, 56 and 98 tablets)
Neperforirana koledarska folija (7, 14, 28, 56 in 98 tablet)
• Some black patients may have a reduced response to this type of medicine, when given as the only treatment, and these patients may need a higher dose.
• Nekateri bolniki-črnci se lahko manj odzovejo na to vrsto zdravil, če jih dobijo kot edino zdravljenje; ti bolniki lahko potrebujejo večji odmerek.
Taking into account the inter-individual variability, a more than average effect can be expected in some patients.
Upoštevaje interindividualno variabilnost je pri nekaterih bolnikih mogoče pričakovati nadpovprečen učinek.
This is also the case for candesartan.
To velja tudi za kandesartan.
The CHMP discussed the rational for this exclusion.
CHMP je razpravljal o osnovi za to izključitev.
If you are using certain medicines, your doctor may need to do blood tests from time to time.
Če jemljete določena zdravila, vam bo zdravnik morda moral od časa do časa opraviti preiskave krvi.
Atacand should be taken once daily with or without food.
Atacand je treba jemati enkrat na dan s hrano ali brez nje.
This corresponds to a relative risk reduction of 15%.
To ustreza zmanjšanju relativnega tveganja za 15 %.
This corresponds to a relative risk reduction of 23%.
To ustreza zmanjšanju relativnega tveganja za 23 %.
In particular, tell your doctor if you are using any of the following medicines:
Še zlasti morate zdravniku povedati, če jemljete katero od naslednjih zdravil:
A number of areas of disharmony were considered, in particular sections 4.1, 4.2, 4.3 and 4.4 of the summary of product characteristics (SPC).
Obravnavana so bila številna področja neusklajenosti, zlasti poglavja 4.1, 4.2, 4.3 in 4.4 v povzetkih glavnih značilnosti zdravila.
The beneficial effects of candesartan were consistent irrespective of age, gender and concomitant medication.
Ugodni učinki kandesartana so bili dosledni ne glede na starost, spol in sočasna zdravila.
In addition, there was no compelling indication that the results in any NYHA class subgroup were notably different from those described for the overall population.
Poleg tega ni bilo pomembnih znakov, da so bili rezultati v kateri koli podskupini po NYHA bistveno drugačni od tistih, ki so bili opisani za celotno populacijo.
It has no agonist activity.
Nima antagonističnega delovanja.
There was no evidence of carcinogenicity.
Dokazov o kancerogenosti ni bilo.
The CHMP thus endorsed the wording “Essential hypertension”.
CHMP je potrdil besedilo: „esencialna hipertenzija.“
Stop taking Atacand and seek medical help immediately if you have any of the following allergic reactions:
Prenehajte jemati zdravilo Atacand in nemudoma poiščite zdravniško pomoč, če se vam pojavi katera od naslednjih alergijskih reakcij:
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF ATACAND AND ASSOCIATED NAMES (SEE ANNEX I)
SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA ATACAND IN Z NJIM POVEZANIH IMEN (GLEJTE DODATEK I)
With continuous treatment, most of the reduction in blood pressure with any dose is generally attained within four weeks and is sustained during long-term treatment.
Med stalnim zdravljenjem je večina znižanja krvnega tlaka z vsemi odmerki na splošno dosežena v štirih tednih in se med dolgotrajnim zdravljenjem ohrani.
Candesartan is highly bound to plasma protein (more than 99%).
Kandesartan je v veliki meri vezan na beljakovine v plazmi (več kot 99 %).
The terminal half-life of candesartan is approximately 9 hours.
Terminalni razpolovni čas kandesartana je približno 9 ur.
Detailed information on this product is available on the website of : {name of MS/Agency}
Podrobne informacije o zdravilu so objavljene na spletni strani: {Ime DČ/Agencije}
The estimated absolute bioavailability of the tablet is therefore 14%.
Ocenjena absolutna biološka uporabnost tablet je tako 14 %.
All-cause mortality was not statistically significant when examined separately in each of the three CHARM studies.
Glede umrljivosti zaradi vseh vzrokov ni bilo statistično značilnih razlik v primeru ločene analize vsake od treh študij CHARM posebej.
Available interaction studies indicate no effect on CYP2C9 and CYP3A4.
Študije, ki so na voljo, ne kažejo vpliva na CYP2C9 in CYP3A4.
Therefore do not stop taking Atacand without first talking to your doctor.
Zato ne nehajte jemati zdravila Atacand, ne da bi se prej posvetovali s svojim zdravnikom.
The apparent volume of distribution of candesartan is 0.1 l/kg.
Navidezni volumen porazdelitve kandesartana je 0,1 l/kg.
If symptomatic hypotension should occur, symptomatic treatment should be instituted and vital signs monitored.
Če se pojavi simptomatska hipotenzija, je treba uvesti simptomatsko zdravljenje in kontrolirati vitalne znake.
Your doctor will normally advise you to stop taking Atacand before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Atacand.
Zdravnik vam bo navadno svetoval, da prenehate jemati zdravilo Atacand preden zanosite ali takoj, ko boste izvedeli, da ste noseči in vam svetoval, da začnete jemati drugo zdravilo namesto zdravila Atacand.
• Water tablets (diuretics).
• tablete za odvajanje vode (diuretike).
Important information about some of the ingredients of Atacand Atacand contains lactose which is a type of sugar.
Pomembne informacije o nekaterih sestavinah zdravila Atacand Zdravilo Atacand vsebuje laktozo, ki je vrsta sladkorja.
Please tell your doctor or pharmacist if you are using, or have recently used, any other medicines, including medicines obtained without a prescription.
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Regarding heart failure, the presentation of the results for the CHARM programme was harmonised.
V zvezi s srčnim popuščanjem je bila usklajena predstavitev rezultatov programa CHARM.
Very rare (affects less than 1 user in 10,000)
Zelo redki (pojavijo se pri manj kot 1 od 10.000 bolnikov)
AIIRAs should not be initiated during pregnancy.
Zdravljenja z AIIRA ne smemo začeti med nosečnostjo.
High blood pressure:
Visok krvni tlak:
• Acetylsalicylic acid (if you are taking more than 3 g each day) (medicine to relieve pain and inflammation).
• acetilsalicilno kislino (če jo jemljete več kot 3 g vsak dan) (zdravilo za lajšanje bolečin in ublažitev vnetja).
It is important that you are aware of what these side effects may be.
Pomembno je, da veste, kakšni so lahko neželeni učinki.
There is currently no data on the effect of candesartan on the progression to diabetic nephropathy.
Trenutno ni podatkov o učinku kandesartana na napredovanje diabetične nefropatije.
Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs.
Medtem, ko ni na voljo nadzorovanih epidemioloških podatkov o tveganju z uporabo AIIRA, lahko za to skupino zdravil obstaja podobno tveganje.
The presentation of results of a study in hypertension in the elderly was also harmonised.
Usklajena je bila tudi predstavitev rezultatov študije hipertenzije pri starostnikih.
If this happens contact your doctor.
Če se to zgodi, se posvetujte z zdravnikom.
There is no indication of serious or exaggerated first dose hypotension or rebound effect after cessation of treatment.
Ni znakov, da bi se po prvem odmerku pojavila resna ali čezmerna hipotenzija, ali da bi se po prenehanju zdravljenja pojavil povratni učinek.
Your doctor may occasionally do blood tests to check whether Atacand has had any effect on your blood (agranulocytosis).
Zdravnik vam bo morda občasno opravil preiskavo krvi, da bo preveril, ali vam zdravilo Atacand vpliva na kri (agranulocitoza).
• severe itching of the skin (with raised lumps)
• hudo srbenje kože (z dvignjenimi izboklinami).
• if you are more than 3 months pregnant (it is also better to avoid Atacand in early pregnancysee pregnancy section).
• če ste noseči več kot 3 mesece (dobro je, da se zdravilu Atacand izognete tudi v zgodnji nosečnosti - glete poglavje o nosečnosti).
In controlled clinical studies adverse reactions were mild and transient.
V kontroliranih kliničnih študijah so bili neželeni učinki blagi in prehodni.
Atacand and associated names (see Annex I) 2 mg tablets Atacand and associated names (see Annex I) 4 mg tablets Atacand and associated names (see Annex I) 8 mg tablets Atacand and associated names (see Annex I) 16 mg tablets Atacand and associated names (see Annex I) 32 mg tablets
Atacand in povezana imena (glejte Dodatek I) 2 mg tablete Atacand in povezana imena (glejte Dodatek I) 4 mg tablete Atacand in povezana imena (glejte Dodatek I) 8 mg tablete Atacand in povezana imena (glejte Dodatek I) 16 mg tablete Atacand in povezana imena (glejte Dodatek I) 32 mg tablete
• Respiratory infection.
• Okužba dihal.
After 6 months of treatment 63% of the patients still taking candesartan cilexetil (89%) were at the target dose of 32 mg.
Po 6 mesecih zdravljenja je 63 % bolnikov, ki so še vedno jemali cileksetilkandesartanat (89 %), uporabljalo ciljni odmerek 32 mg.
The relative bioavailability of the tablet formulation compared with the same oral solution is approximately 34% with very little variability.
Relativna biološka uporabnost tablet v primerjavi z isto peroralno raztopino je približno 34 % in kaže zelo majhno variabilnost.
No studies on the effects of candesartan on the ability to drive and use machines have been performed.
Študije o vplivih kandesartana na sposobnost vožnje in upravljanja s stroji niso bile izvedene.
These changes were considered to be caused by the pharmacological action of candesartan.
Te spremembe so ocenili za posledice farmakološkega delovanja kandesartana.